[1] The pivotal SURPASS trials, which evaluated tirzepatide in over 6,000 patients with type 2 diabetes, did not identify pharyngitis or throat pain as a significant treatment-related adverse event
When the acetyl-CoA generated from the beta-oxidation of fats enters the Krebs cycle, it undergoes a series of transformations, eventually reaching the stage where succinate is converted into fumarate by the enzyme succinate dehydrogenase
A brand NDA lists: (1) the compound patent, expiring 2026
The honest answer is limited, but not zero
Headaches: Some users report headaches, which may be due to changes in blood sugar levels or GH fluctuations
Thus, all adjuvant glucose-lowering therapies in type 1 diabetes are used off-label and contrary to local and national guidance [16]